Show simple item record

dc.creatorLazarević-Pašti, Tamara
dc.creatorLeskovac, Andreja
dc.creatorMomić, Tatjana
dc.creatorPetrović, Sandra
dc.creatorVasić, Vesna M.
dc.date.accessioned2018-03-01T17:56:54Z
dc.date.available2018-03-01T17:56:54Z
dc.date.issued2017
dc.identifier.issn0929-8673 (print)
dc.identifier.issn1875-533X (electronic)
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/1796
dc.description.abstractBackground: Acetylcholinesterase (AChE) is involved in the termination of impulse transmission by rapid hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the central and peripheral nervous systems. The enzyme inactivation leads to acetylcholine accumulation, hyperstimulation of nicotinic and muscarinic receptors, and disrupted neurotransmission. Hence, acetylcholinesterase inhibitors, interacting with the enzyme as their primary target, are applied as relevant drugs for different neurodegenerative diseases (such as Alzheimers and Parkinsons) as well as toxins. At the same time, there are increasing evidence that in non-neuronal context, AChE is involved in the regulation of cell proliferation, differentiation, apoptosis and cell-cell interaction. An irregular expression of AChE has been found in different types of tumors, suggesting the involvement of AChE in the regulation of tumor development. Having all this in mind, there is a possibility that some AChE inhibitors could be used as anti-cancer agents. Objective: This contribution will discuss a broad range of possible application of different AChE inhibitors as drugs, from well-known anti-Alzheimers disease drugs to their use in cancer treatment in future. Emphasis will be put on various known AChE inhibitors classes, whose application as drugs could be controversy, as well as on newly investigated natural products, which can also modulate AChE activity. Conclusion: It is not clear a patient treated for neurodegenerative condition prone to increased risk for some types of cancer and vice versa. This is necessary to keep in mind during rational drug design process for all therapies, which are based on AChE as a target molecule.en
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172023/RS//
dc.rightsrestrictedAccessen
dc.sourceCurrent Medicinal Chemistryen
dc.subjectacetylcholinesteraseen
dc.subjectAlzheimers diseaseen
dc.subjectParkinsons diseaseen
dc.subjectcancer treatmenten
dc.subjectdrug designen
dc.subjectapoptosisen
dc.titleModulators of Acetylcholinesterase Activity: From Alzheimers Disease to Anti-Cancer Drugsen
dc.typereviewen
dcterms.abstractЛазаревић-Пасти Тамара; Лесковац Aндреја; Момић Татјана; Петровић, Сандра; Васић Весна М;
dc.citation.volume24
dc.citation.issue30
dc.citation.spage3283
dc.citation.epage3309
dc.identifier.wos000413747600005
dc.identifier.doi10.2174/0929867324666170705123509
dc.identifier.pmid28685687
dc.identifier.scopus2-s2.0-85040048287


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record